HIV incidence and mortality decreased globally, yet increased markedly in the Commonwealth of Independent States (CIS) of Eastern Europe and Central Asia where HIV epidemics remain volatile and fueled primarily by people who inject drugs (PWIDs) with opioid use disorders (OUDs). Regional drug policies favoring incarceration have resulted in 5 CIS countries being among the 10 countries with the highest rate of incarceration. In this region, HIV is concentrated 18- to 50-fold higher than in communities. Data from multiple settings where PWIDs and people living with HIV (PLH) are concentrated (i.e., prisons) reveal that such structured settings can be effective sites for HIV prevention. In the absence of preventive evidence-based interventions (EBIs), prisoners often engage in risky HIV behaviors both within prison and post-release. One of the most effective HIV prevention EBI is opioid substitution therapy (OST), but this EBI is mostly absent from or markedly under-scaled in CIS prisons. We have successfully completed and exceeded our original 3 aims. First, we created a new research collaboration called PRIDE (Prison-related Research, Intervention Development and Evaluation), which focuses on integrating research and policy with Prison Departments and local and international stakeholders in CIS countries. Second, we exceeded the number of biosurveillance prison surveys conducted and established a new method that is now endorsed by CDC, WHO and UNODC. We documented the extraordinary burden of HIV, other infectious diseases and substance use disorders, and community-transition challenges and recorded the highest recorded rate of within-prison drug injection among HIV+ prisoners. Third, we uncovered markedly negative attitudes toward OST, PWIDs and PLH among prison personnel, which was mediated by provision of accurate knowledge and could be improved using a brief intervention that we adapted from social marketing and decision science strategies. Fourth, we assisted with introducing pilot OST programs in two CIS countries. Last, because none of the countries had transitional care programs, including the ones where we introduced OST, we began the process of developing a MATLINK protocol (linkage to OST), that is based on another EBI - SBIRT (screening, brief intervention and referral to treatment). Findings presented to local and PRIDE stakeholders resulted in the request by several member countries to focus on either introducing or expanding OST within prisons, an EBI, or where local laws, policy or cultures were uncommitted, all PRIDE stakeholders stated their commitment to linking prisoners to OST post-release. This renewal application builds on our existing implementation science framework where we propose a series of related activities that involve improving access to OST either within prison and/or linking them to it post-release. Our three related specific aims involve creating and pilot testing culturally congruent MATLINK protocols within partner countries, assessing organizational barriers to MATLINK and intervening with prison staff, and using a multi-level implementation science framework, assessing client-level outcomes for the MATLINK protocol in each setting. Our productive team consists of international researchers and collaborating sites with demonstrated successes working in the political and legal context in CIS countries and prisons. Our collective research experience includes implementation science, criminal justice settings, introducing and expanding OST, EBIs, and HIV prevention.

Public Health Relevance

Prisons concentrate people who inject drugs and people living with HIV, especially in the Commonwealth of Independent States of the former Soviet Union, where the HIV epidemic and drug injectors and their sexual partners remains volatile. Introducing and expanding an evidence-based HIV prevention strategy like opioid substitution therapy within the prisons in a legal, political and cultural context is fraught with barriers that involve the client, prison staff and the criminal justice infrastructure. Implementation science strategies are effective approaches to study and promote intervention effectiveness that simultaneously works to overcome barriers at each level.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
3R01DA029910-07S1
Application #
9479824
Study Section
Special Emphasis Panel (ZRG1-AARR-F (90)S)
Program Officer
Jones, Dionne
Project Start
2010-09-01
Project End
2020-07-31
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
7
Fiscal Year
2017
Total Cost
$8,467
Indirect Cost
$627
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Makarenko, Iuliia; Mazhnaya, Alyona; Marcus, Ruthanne et al. (2018) Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine. J Subst Abuse Treat 87:1-8
Marcus, Ruthanne; Bojko, Martha J; Mazhnaya, Alyona et al. (2018) A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine. J Subst Abuse Treat 86:86-93
Zelenev, Alexei; Shea, Portia; Mazhnaya, Alyona et al. (2018) Assessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine. Drug Alcohol Depend 190:82-88
Stone, Jack; Fraser, Hannah; Lim, Aaron G et al. (2018) Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect Dis 18:1397-1409
Rozanova, Julia; Morozova, Olga; Azbel, Lyuba et al. (2018) Perceptions of Health-Related Community Reentry Challenges among Incarcerated Drug Users in Azerbaijan, Kyrgyzstan, and Ukraine. J Urban Health 95:508-522
Mazhnaya, Alyona; Meteliuk, Anna; Barnard, Tetiana et al. (2017) Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes. Int J Drug Policy 47:187-195
Marcus, Ruthanne; Makarenko, Iuliia; Mazhnaya, Alyona et al. (2017) Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug Alcohol Depend 179:213-219
Makarenko, Iuliia; Mazhnaya, Alyona; Marcus, Ruthanne et al. (2017) Willingness to pay for opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. Int J Drug Policy 45:56-63
Azbel, Lyuba; Rozanova, Julia; Michels, Ingo et al. (2017) A qualitative assessment of an abstinence-oriented therapeutic community for prisoners with substance use disorders in Kyrgyzstan. Harm Reduct J 14:43
Ghosh, Debarchana; Krishnan, Archana; Gibson, Britton et al. (2017) Social Network Strategies to Address HIV Prevention and Treatment Continuum of Care Among At-risk and HIV-infected Substance Users: A Systematic Scoping Review. AIDS Behav 21:1183-1207

Showing the most recent 10 out of 48 publications